AVACINCAPTAD PEGOL SODIUM
| Brand name | IZERVAY |
|---|---|
| Active ingredient | AVACINCAPTAD PEGOL SODIUM |
| Strength | EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) |
| Dosage form | SOLUTION |
| Route | INTRAVITREAL |
| Modality | Small molecule |
| FDA approval | August 2023 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11491176 | July 2034 | use U-3673 |
| 11273171 | July 2034 | use U-3673 |
| 12016875 | July 2034 | use U-3673 |
| 9617546 | February 2027 | substance |
| 7579456 | February 2027 | substance |
| 8236773 | November 2026 | use U-3673 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.